Washington Mudini1,2, Joel M Palefsky3, Martin J Hale1,2, Michael Z Chirenje4, Rudo Makunike-Mutasa5, Fiona Mutisi4, Alltalents Murahwa6, Altini Mario1. 1. Department of Anatomical Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 2. Department of Health, National Health Laboratory Service, Johannesburg, South Africa. 3. Department of Medicine, University of California, San Francisco, CA. 4. University of Zimbabwe-University of California, San Francisco Collaborative Research Program, University of Zimbabwe, Harare, Zimbabwe. 5. Department of Histopathology, College of Health Sciences, University of Zimbabwe, Harare Zimbabwe. 6. Department of Immunology, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Abstract
BACKGROUND: Invasive cervical carcinoma (ICC) accounts for 23% of all cancer-related deaths in Zimbabwean women. Trials for a national program of genotype-specific human papillomavirus (HPV) vaccines are underway to prevent cervical carcinoma, but the distribution of HPV types among women with ICC according to HIV status is unknown. METHODS: To determine prevalence and distribution of high-risk HPV genotypes by HIV status in women with ICC, we performed a cross-sectional study on women referred for ICC testing at 4 urban referral hospitals in Zimbabwe from June 2014 to December 2015. Cervical biopsies were obtained for histology and HPV genotyping. HIV serology testing was performed. HPV testing was performed using MY09/MY11 polymerase chain reaction followed by typing using dot-blot hybridization. RESULTS: Of 107 participants with histologically proven ICC, HIV prevalence was 49.5% (53/107). HIV-positive women tended to be younger (median age 44 years) than HIV-negative women (median age 59 years). HPV prevalence was 94% (101/107), ranging from 1 to 5 genotypes per participant. HPV 16 (81.5%), 18 (24%), 33 (13%), 35 (11%), 56 (9%), and 45 (7.4%) were the most prevalent genotypes among HIV-negative participants; HPV 16 (67.9%), 18 (43.4%), 56 (18.9%), 45 (15.1%), 33 (11.3%), and 58 (9.4%) were the most prevalent among HIV-positive participants. Eighty-three percent of women were infected with either HPV-16 or HPV-18. CONCLUSIONS: Effective vaccination programs against HPV 16 and HPV 18 could prevent up to 83% of cases of cervical cancer in Zimbabwe. HIV may influence distribution of some HPV genotypes given the significant increase in prevalence of HPV 18 among HIV-positive participants.
BACKGROUND:Invasive cervical carcinoma (ICC) accounts for 23% of all cancer-related deaths in Zimbabwean women. Trials for a national program of genotype-specific human papillomavirus (HPV) vaccines are underway to prevent cervical carcinoma, but the distribution of HPV types among women with ICC according to HIV status is unknown. METHODS: To determine prevalence and distribution of high-risk HPV genotypes by HIV status in women with ICC, we performed a cross-sectional study on women referred for ICC testing at 4 urban referral hospitals in Zimbabwe from June 2014 to December 2015. Cervical biopsies were obtained for histology and HPV genotyping. HIV serology testing was performed. HPV testing was performed using MY09/MY11 polymerase chain reaction followed by typing using dot-blot hybridization. RESULTS: Of 107 participants with histologically proven ICC, HIV prevalence was 49.5% (53/107). HIV-positive women tended to be younger (median age 44 years) than HIV-negative women (median age 59 years). HPV prevalence was 94% (101/107), ranging from 1 to 5 genotypes per participant. HPV 16 (81.5%), 18 (24%), 33 (13%), 35 (11%), 56 (9%), and 45 (7.4%) were the most prevalent genotypes among HIV-negative participants; HPV 16 (67.9%), 18 (43.4%), 56 (18.9%), 45 (15.1%), 33 (11.3%), and 58 (9.4%) were the most prevalent among HIV-positive participants. Eighty-three percent of women were infected with either HPV-16 or HPV-18. CONCLUSIONS: Effective vaccination programs against HPV 16 and HPV 18 could prevent up to 83% of cases of cervical cancer in Zimbabwe. HIV may influence distribution of some HPV genotypes given the significant increase in prevalence of HPV 18 among HIV-positive participants.
Authors: Jennifer S Smith; Lisa Lindsay; Brooke Hoots; Jessica Keys; Silvia Franceschi; Rachel Winer; Gary M Clifford Journal: Int J Cancer Date: 2007-08-01 Impact factor: 7.396
Authors: Tiffany G Harris; Robert D Burk; Joel M Palefsky; L Stewart Massad; Ji Yon Bang; Kathryn Anastos; Howard Minkoff; Charles B Hall; Melanie C Bacon; Alexandra M Levine; D Heather Watts; Michael J Silverberg; Xiaonan Xue; Sandra L Melnick; Howard D Strickler Journal: JAMA Date: 2005-03-23 Impact factor: 56.272
Authors: Howard D Strickler; Joel M Palefsky; Keerti V Shah; Kathryn Anastos; Robert S Klein; Howard Minkoff; Ann Duerr; L Stewart Massad; David D Celentano; Charles Hall; Melissa Fazzari; Susan Cu-Uvin; Melanie Bacon; Paula Schuman; Alexandra M Levine; Amanda J Durante; Stephen Gange; Sandra Melnick; Robert D Burk Journal: J Natl Cancer Inst Date: 2003-07-16 Impact factor: 13.506
Authors: Cathy Ndiaye; Laia Alemany; Nafissatou Ndiaye; Bakarou Kamaté; Yankhoba Diop; Michael Odida; Kunbi Banjo; Sara Tous; Jo Ellen Klaustermeier; Omar Clavero; Xavier Castellsagué; F Xavier Bosch; Helen Trottier; Silvia de Sanjosé Journal: Trop Med Int Health Date: 2012-10-29 Impact factor: 2.622
Authors: Cynthia Firnhaber; Hoa Van Le; Audrey Pettifor; Doreen Schulze; Pam Michelow; Ian M Sanne; David A Lewis; Anna-Lise Williamson; Bruce Allan; Sophia Williams; Allen Rinas; Simon Levin; Jennifer S Smith Journal: Cancer Causes Control Date: 2009-12-01 Impact factor: 2.506
Authors: Ismaheel O Lawal; Thabo Lengana; Charl Janse van Rensburg; Florette Reyneke; Gbenga O Popoola; Alfred O Ankrah; Mike M Sathekge Journal: PLoS One Date: 2019-04-18 Impact factor: 3.240
Authors: Ahmadaye Ibrahim Khalil; Tharcisse Mpunga; Feixue Wei; Iacopo Baussano; Catherine de Martel; Freddie Bray; Dominik Stelzle; Scott Dryden-Peterson; Antoine Jaquet; Marie-Josèphe Horner; Olutosin A Awolude; Mario Jesus Trejo; Washington Mudini; Amr S Soliman; Mazvita Sengayi-Muchengeti; Anna E Coghill; Matthys C van Aardt; Hugo De Vuyst; Stephen E Hawes; Nathalie Broutet; Shona Dalal; Gary M Clifford Journal: Int J Cancer Date: 2021-10-19 Impact factor: 7.316
Authors: Oppah Kuguyo; Racheal S Dube Mandishora; Nicholas Ekow Thomford; Rudo Makunike-Mutasa; Charles F B Nhachi; Alice Matimba; Collet Dandara Journal: PLoS One Date: 2021-09-28 Impact factor: 3.240